| Similar Articles |
|---|
 |
American Family Physician
August 1, 2002
Daphne P. Bicket |
Using ACE Inhibitors Appropriately Although angiotensin-converting enzyme (ACE) inhibitors have documented clinical benefits in a variety of clinical situations, the disparity between the evidence from clinical trials and bedside medicine is well documented.   |
American Family Physician
September 1, 2003
Magill et al. |
New Developments in the Management of Hypertension Advances in the management of hypertension have refined our understanding of systolic blood pressure, nutrition, medication selection, and hypertension in special populations. |
American Family Physician
February 1, 2005
Dickerson & Gibson |
Management of Hypertension in Older Persons Antihypertensive therapy has been shown to reduce morbidity and mortality in older patients with elevated systolic or diastolic blood pressures. |
American Family Physician
December 1, 2004
McConaghy & Smith |
Outpatient Treatment of Systolic Heart Failure Optimal outpatient treatment of systolic heart failure has three goals that should be pursued simultaneously: (1) control of risk factors for the development and progression of heart failure, (2) treatment of heart failure, and (3) education of patients. |
Nursing
March 2012
Daniel A. Hussar |
New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs. |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
Nurse Practitioner
February 2011
Jennifer M. Belavic |
Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
Nurse Practitioner
July 2010
Kristine A. Scordo |
Treating antiretroviral-induced dyslipidemia in HIV-infected adults Studies indicate that HIV-infected patients (both males and females) may be at an increased risk for the development of cardiovascular disease |
Nursing
May 2010
Debra Castner |
Understanding the stages of chronic kidney disease This article will help you to recognize CKD and understand its stages so you can help your patient to modify risk factors, prevent further kidney damage, and manage complications. First, consider the scope of the problem. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
Nursing
January 2011
Carl A. Kirton |
HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness. |
The Motley Fool
November 29, 2010
Brian Orelli |
Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily. |
Managed Care
August 2007 |
The Formulary Files ARB costs run high in Medicare Part D. |
The Motley Fool
December 15, 2010
Brian Orelli |
Beautiful Efficacy, Wrong Pill Lexicon Pharmaceuticals presented beautiful data showing a pill it gave rheumatoid arthritis patients decreased symptoms in 49% of patients. Unfortunately, the pill was a dummy pill with no active ingredient. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
August 11, 2010
Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
The Motley Fool
March 31, 2010
Brian Orelli |
How Do You Put a Price on Pain? Price controls could wreck havoc on expensive therapies that control pain. |
